These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1262 related articles for article (PubMed ID: 826316)

  • 21. N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin.
    Israel M; Modest EJ; Frei E
    Cancer Res; 1975 May; 35(5):1365-8. PubMed ID: 1054622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
    Goldin A; Venditti JM; Geran R
    Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Experimental evaluation of anthracycline analogs.
    Casazza AM
    Cancer Treat Rep; 1979 May; 63(5):835-44. PubMed ID: 455325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R; Dasdia T; Galatulas I; Zunino F
    Anticancer Res; 1986; 6(5):1037-9. PubMed ID: 3099628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adriamycin (NSC-123127) and its analogs.
    Henry DW
    Cancer Chemother Rep 2; 1974 Dec; 4(4):5-9. PubMed ID: 4451911
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of the antileukemic effect in mice of adriamycin (NSC-123127) with daunomycin (NSC-82151).
    Sandberg JS; Howsden FL; DiMarco A; Goldin A
    Cancer Chemother Rep; 1970 Feb; 54(1):1-7. PubMed ID: 5527012
    [No Abstract]   [Full Text] [Related]  

  • 27. Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A.
    Rose WC; Schurig JE; Huftalen JB; Bradner WT
    Cancer Res; 1983 Apr; 43(4):1504-10. PubMed ID: 6831399
    [No Abstract]   [Full Text] [Related]  

  • 28. A new anthracycline metabolite D788-1 (10-carboxy-13-deoxocarminomycin) in daunorubicin beer.
    Fujii S; Kubo K; Johdo O; Yoshimoto A; Ishikura T; Naganawa H; Sawa T; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1986 Mar; 39(3):473-5. PubMed ID: 3700249
    [No Abstract]   [Full Text] [Related]  

  • 29. N-salicylidene derivatives of pirarubicin.
    Ajito K; Ikeda D; Komuro K; Nosaka C; Wako N; Kondo S; Takeuchi T
    J Antibiot (Tokyo); 1989 Jul; 42(7):1133-44. PubMed ID: 2753818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The anthracycline antineoplastic drugs.
    Young RC; Ozols RF; Myers CE
    N Engl J Med; 1981 Jul; 305(3):139-53. PubMed ID: 7017406
    [No Abstract]   [Full Text] [Related]  

  • 31. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M; Nagashima K
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potentiation of actinomycin D or adriamycin antitumor activity with DNA.
    Marks TA; Venditti JM
    Cancer Res; 1976 Feb; 36(2 Pt 1):496-504. PubMed ID: 1260747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative characteristics of the antitumor and immunodepressive activity of carminomycin on the L-1210 experimental model].
    Berezina TA; Uteshev BS
    Antibiotiki; 1979 Oct; 24(10):767-71. PubMed ID: 496420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inability of amphotericin B(Fungizone) or of sodium deoxycholate to alter natural drug resistance or sensitivity of transplanted murine leukemias.
    Ganu UK; Khandalekar DD; Gokhale SV
    Indian J Physiol Pharmacol; 1984; 28(1):21-6. PubMed ID: 6490126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
    Kessel D; Wilberding C
    Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
    Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
    Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
    Young CW; Raymond V
    Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
    [No Abstract]   [Full Text] [Related]  

  • 38. Antileukemic activity of 4-demethoxydaunorubicin in mice.
    Casazza AM; Pratesi G; Giuliani F; Di Marco A
    Tumori; 1980 Oct; 66(5):549-64. PubMed ID: 6936969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3'-deamino-3'-morpholino derivatives of daunomycin, adriamycin and carminomycin.
    Takahashi Y; Kinoshita M; Masuda T; Tatsuta K; Takeuchi T; Umezawa H
    J Antibiot (Tokyo); 1982 Jan; 35(1):117-8. PubMed ID: 7068512
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.